Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

Size: px
Start display at page:

Download "Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment"

Transcription

1 Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are: Subacute and/or progressive headaches that worsen over time (months) A new or different headache Any headache of maximum severity at onset A headache that wakens you from sleep Headache of new onset after age 50 Persistent headache precipitated by a Valsalva maneuver Evidence such as fever, hypertension, myalgias, weight loss or scalp tenderness suggesting a systemic disorder Presence of neurological signs that may suggest a secondary cause Seizures 3. Migraine-associated symptoms are often misdiagnosed as sinus headache by patients and providers. This has led to the underdiagnosis and treatment of migraine. 4. Appropriate pharmacological or analgesic treatment of acute headache should generally not exceed more than two days per week on a regular basis. More treatment other than this may result in medication-overuse chronic daily headaches. 5. Disability from headaches is an important issue for migraineurs. 6. All patients should be considered for prophylactic therapy. 7. Migraines occurring in association with menses and not responsive to standard cyclic prophylaxis may respond to hormonal prophylaxis with the use of estradiol patches or estrogen-containing contraceptives. 8. Women who have migraines with aura have a higher risk of stroke with the use of estrogen-containing contraceptives. Headaches occurring during perimenopause or after menopause may respond to hormonal therapy. 9. Most prophylactic medications should be started in a low dose and titrated to a therapeutic dose to minimize side effects and maintained at target dose for 8-12 weeks to obtain maximum efficacy. 10. Consider referral to addictive medicine program if appropriate. Treatment Goals 1. Increase the accurate diagnosis of headaches 2. Increase the functional status of those with migraine 3. Increase the rate of treatment plans or adherence to plan for mild, moderate and severe headaches for migraineurs 4. Reduce the use of opiates and barbiturates for the treatment of primary headache 5. Increase education for patients with primary headache 6. Increase appropriate prophylactic treatment based on headache type (i.e., migraine, cluster, menstrual-associated) 7. Increase appropriate acute and prophylactic treatment for migraineurs based on level of severity (i.e., mild, moderate, severe) Effective date: August, 2007 Page 1

2 Effective date: August, 2007 Page 2

3 Effective date: August, 2007 Page 3

4 Effective date: August, 2007 Page 4

5 Drug Notes Side Effects Contraindications Acetaminophen Hypersensitivity to acetaminophen Acetaminophen / Aspirin/Caffeine Acetominophen/aspirin mix with caffeine added Aspirin Gastrointestinal * Active peptic ulcer Chlorpromazine (CPZ) injection Thorazine Dexamethasone Decadron DHE (dihydroergotamine mesylate) D.H.E. 45 Type of tranquilizer and anti-psychotic medication used to treat migraines and nausea Anti-inflammatory and steroid medication Type of drug used to treat migraine, rebound, or cluster headaches Drowsiness, extrapyramidal * symptoms Cushingoid * Chest tightness, tingling, nausea disease Hypotension *, previous adverse reaction Ischemic heart disease *, uncontrolled hypertension *, vasospastic angina *, advanced peripheral vascular disease *, pregnancy, ischemic cerebrovascular disease * Nasal spray Migranal Ergotamine by mouth Cafergot Type of drug used to treat migraine, rebound, or cluster headaches, constricts blood vessels, improves blood vessel tone Nasal congestion, throat discomfort, nasal irritation, nausea Chest pain, tingling, nausea See DHE * injection Ischemic heart disease *, uncontrolled hypertension *, vasospastic angina *, advanced peripheral vascular disease *, pregnancy, ischemic cerebrovascular disease * Rectal suppository Cafergot Chest pain, tingling, nausea See Ergotamine by mouth Sublingual (under the tongue) Ergomar Hydrocortisone Solu-Cortef Anti-inflammatory and steroid medication Chest pain, tingling, nausea See Ergotamine by mouth Effective date: August, 2007 Page 5

6 Drug Notes Side Effects Contraindications Isometheptene Mucate 65 mg / Dichloralphenazone 100 mg/ Acetaminophen 325 mg Midrin CIV Type of sedative and combination drug use to treat migraine and tension headache Drowsiness, dizziness Ischemic heart disease *, severe renal disease *, ischemic cerebrovascular disease* Ketorolac IM (inject into the muscle) Toradol Lidocaine 4% Solution * Magnesium Sulfate Opiates Hydromorphone Dilaudid Morphine NSAID (non-steroidal anti-inflammatory) Local anesthetic Electrolyte replenisher and anticonvulsant for treatment of acute (sudden) migraine. Affects muscle constriction and nerve transmission. Type of drug that depresses the central nervous system and used to relieve pain Drowsiness, nausea, dyspepsia * Burning or numbness in nose or pharynx * Flushing, hypotension*, burning sensation in the face and neck Sedation, confusion, risk of habituation Active peptic ulcer disease *, renal insufficiency * Heart block *, severe renal impairment * Meperidine HCL Demerol NSAIDs Ibuprofen Advil Motrin Nuprin Non-steroidal antiinflammatory drug Gastrointestinal * Active peptic ulcer disease *, renal insufficiency * Ketoprofen Orudis K Actron Naproxen Sodium Anaprox Aleve Prochlorperazine IV Compazine Valproate Sodium Depacon Antiemetic (stops nausea or vomiting) Type of antiepileptic medication Gastrointestinal * Gastrointestinal * Drowsiness, extrapyramidal symptoms * Nausea, vomiting, tremor, dizziness See Ibuprofen See Ibuprofen Hypotension * Liver disease, pregnancy Effective date: August, 2007 Page 6

7 Drug Notes Side Effects Contraindications 5-HT Agonists (Triptans) Almotriptan Axert Eletriptan Relpax Frovatriptan Frova Naratriptan Amerge Rizatriptan Maxalt Mazalt MLT Sumatriptan Imitrex by mouth Nasal spray Subcutaneous (inject into the skin) Zolmitriptan Zomig Zomig-ZMT by mouth Medications specific to the treatment of migraine and cluster headaches Tingling, nausea, dry mouth, drowsiness, chest tightness (26% of time) Dizziness, drowsiness, nausea, dry mouth, paresthesia *, chest/abdominal tightness, vomiting, dysphagia * Chest tightness, flushing, dizziness, tingling, fatigue Chest/throat tightness, tingling, flushing, dizziness, nausea Chest/throat tightness, dizziness, tingling Chest tightness, tingling, flushing, dizziness, limb heaviness, nausea Chest/throat tightness Chest/throat tightness Chest/throat tightness, tingling, flushing, dizziness, nausea Not to be used within 72 hours of treatment with the following potent CYP3A4 inhibitors: ketocomazole, itracomazole, mefazodome, troleandomycin, clarithromycin, ritomavir, nelfinavir Hypertension*, vasospastic angina*, peripheral vascular disease*, pregnancy, ischemic cerebrovascular disease*, use of other 5-HT agonists* or ergotamines* if used within 24 hours Ischemic heart disease*, uncontrolled hypertension*, vasospastic angina*, peripheral vascular disease*, pregnancy, ischemic cerebrovascular disease*, use of 5-HT agonists* or ergotamines* if used within 24 hours, use of MAO inhibitors* within 2 weeks Nasal spray Effective date: August, 2007 Page 7

8 Drug Notes Side Effects Contraindications Antiepileptics Divalproex Sodium (valponate sodium) Depakote Depakote-ER (time release) Anti epileptic and anticonvulsant drugs Nausea, tremor, weight gain, alopecia*, increased LFTs* Avoid in patients with liver disease, pregnancy Gabapentin Neurontin Dizziness, somnolence*, peripheral edema*, fatigue, ataxia*, nervousness, tremor, weight gain Topiramate Topamax Beta-Blockers Atenolol Tenormin Metoprolol Lopressor Heart medication Somnolence*, nervousness, fatigue, dizziness, confusion, anorexia*, ataxia*, acute-angle closure of glaucoma*, nausea, metabolic acidosis*, paresthesias*, kidney stones Fatigue, bronchospasm*, bradycardia*, hypotension*, CHF*, depression, impotence*, decreased libido*, sleep disturbance Reduced renal* or hepatic* functions Sinus bradycardia*, 1 st degree heart block*, acute CHF* Nadolol Corgard Propranolol Inderal Timolol Blocadren Ca+ Channel Blockers Verapamil Calan Veselan Muscle relaxants Tizanidine Zanaflex Tricyclics Amitiptyline Elavil Heart medication Muscle relaxants Constipation, dizziness, edema*, hypotension*, nausea Dry mouth, drowsiness, asthesia*, dizziness, mild hypotension* Atrial fibrillation*, CHF*, sick sinus syndrome*, hypotension*, 2 nd, 3 rd degree heart block* Doxepin Sinequan Nortiptyline Aventyl Pamelor Effective date: August, 2007 Page 8

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine

More information

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: Reference Number: CP.HNMC.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE

COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE HEADACHE CHARACTERISTICS Frequency and Severity 1. At what AGE did you get your first headache, of ANY kind? 2. At what AGE did your headaches

More information

How do we treat migraine? New SIGN Guidelines

How do we treat migraine? New SIGN Guidelines How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood

More information

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am

More information

Disclosures. Triptans for Kids 5/16/13

Disclosures. Triptans for Kids 5/16/13 5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS

More information

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation

More information

Treatments for migraine

Treatments for migraine Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication

More information

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Triptan Quantity Limit

Triptan Quantity Limit *- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5

More information

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily

More information

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu

More information

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim) Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)

More information

How could I be having migraine when I don't have a headache?

How could I be having migraine when I don't have a headache? Migraine Your doctor thinks you may have migraine. Classic migraine attacks start with visual symptoms (often zig-zag colored lights or flashes of light expanding to one side over 10-30 minutes) followed

More information

Headache Questionnaire

Headache Questionnaire Date: All Headache Patients We would appreciate your cooperation in filling out this form. In our evaluation of headache, your history is typically our most valuable tool for diagnosis and subsequent treatment.

More information

Understanding Migraines and Treatment Options. Simplified Diagnosis of Migraine. Migraine Prevalence American Migraine Study II

Understanding Migraines and Treatment Options. Simplified Diagnosis of Migraine. Migraine Prevalence American Migraine Study II Understanding Migraines and Treatment Options Deborah C. Zajac, RN-BC Center for Headache and Pain Neurological Institute Cleveland Clinic Simplified Diagnosis of Migraine Any person with a stable pattern

More information

Anti-Migraine Agents

Anti-Migraine Agents DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

~ ColumbiaDoctors Adult New Patient Intake Form Patient Information

~ ColumbiaDoctors Adult New Patient Intake Form Patient Information ~ ColumbiaDoctors Adult New Patient Intake Form Patient Information Last Name: First Name: DOB: Gender: Home Phone: Mobile Phone: ---------- Preferred Phone: Home or Mobile (circle one) Email: -----------

More information

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline Scottish intercollegiate Guidelines Network SIGN November 2008. PETER FRAMPTON MSc MCOptom BAppSc (Optom)(AUS)

More information

Head Pain Intake Form

Head Pain Intake Form Head Pain Intake Form NEUROLOGY LLC Your evaluation will take one hour to complete and in order to best utilize the time, please take the time to complete this questionnaire prior to your appointment.

More information

TREXIMET UTILIZATION MANAGEMENT CRITERIA

TREXIMET UTILIZATION MANAGEMENT CRITERIA TREXIMET UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: 5HT1 agonists Treximet (sumatriptan/naproxen sodium) 85 mg / 500 mg tablet FDA INDICATIONS: Sumatriptan/naproxen is indicated

More information

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Maxalt Page: 1 of 5 Last Review Date: March 18, 2016 Maxalt Description Maxalt / Maxalt-MLT (rizatriptan)

More information

Update on Diagnosis and Management of Migraines

Update on Diagnosis and Management of Migraines Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish

More information

Treatment of Primary Headache Syndromes

Treatment of Primary Headache Syndromes Presenter Disclosure Information 2:45 3:45pm Treatment of Primary Headache Syndromes SPEAKER Gerald W. Smetana, MD The following relationships exist related to this presentation: Gerald W.Smetana, MD,

More information

Management of headache

Management of headache Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,

More information

Drug Name (select from list of drugs shown / provide drug information) Patient Information. Prescribing Physician

Drug Name (select from list of drugs shown / provide drug information) Patient Information. Prescribing Physician Texas Standard Prior Authorization Form Addendum MOLINA TX MARKETPLACE Botulinum Toxins CL Molina Universal This fax machine is located in a secure location as required by HIPAA Regulations. Complete /

More information

IMITREX UTILIZATION MANAGEMENT CRITERIA

IMITREX UTILIZATION MANAGEMENT CRITERIA IMITREX UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: 5HT1 agonists BRAND NAME: Imitrex 4 mg injection kit or refill (Generic) (sumatriptan) 6 mg injection kit or refill Injection vial (1 dose) 5 mg nasal

More information

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: June 22, 2017 Migranal Nasal Spray

More information

Strategies in Migraine Care

Strategies in Migraine Care Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives

More information

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type. Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369

More information

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray

More information

1. On how many days in the last 3 months did you miss work or school because of your headaches?

1. On how many days in the last 3 months did you miss work or school because of your headaches? The Migraine Disability Assessment Test The MIDAS (Migraine Disability Assessment) questionnaire was put together to help you measure the impact your headaches have on your life. The information on this

More information

Triptans Quantity Limit Program Summary

Triptans Quantity Limit Program Summary Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without

More information

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off

More information

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau: Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants

More information

My patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D.

My patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D. My patient s pain in the head, is a pain in the @%$*&# Greg Jicha, M.D., Ph.D. Kentucky Neurologic Institute University of Kentucky, Lexington, KY Migraine is More Common than Asthma & Diabetes Combined

More information

UTILIZATION MANAGEMENT CRITERIA

UTILIZATION MANAGEMENT CRITERIA SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),

More information

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES 1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International

More information

Understanding Migraines

Understanding Migraines Understanding Migraines Migraine is a severe headache syndrome that recurs. Migraine headaches are usually throbbing, but may also be described as exploding, shooting, or squeezing. Migraine headaches

More information

Outline. Etiology. General information. Definition 4/13/2012

Outline. Etiology. General information. Definition 4/13/2012 Outline Dr. Susan Fralick-Ball, PsyD, MSN, RN, CH, CLNC PsychMedEd for Advance 2012 Etiology, Stages & Classifications of Migraines Differential Pathophysiology from other Headaches Current Treatment Therapies

More information

Approach to a Patient with Headache

Approach to a Patient with Headache Approach to a Patient with Headache J.D. Bartleson, MD Professor of Neurology Mayo Clinic College of Medicine 15 th Annual Internal Medicine Conference March 25, 2018 Boca Raton, FL 2014 MFMER slide-1

More information

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan

More information

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact

More information

ONZETRA XSAIL (sumatriptan) nasal powder

ONZETRA XSAIL (sumatriptan) nasal powder ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 5 Last Review Date: December 2, 2016 Sumatriptan Description Sumatriptan

More information

Headache A Practical Approach

Headache A Practical Approach Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:

More information

disease or in clients who consume alcohol on a regular basis. bilirubin

disease or in clients who consume alcohol on a regular basis. bilirubin NON-OPIOID Acetaminophen(Tylenol) Therapeutic class: Analgesic, antipyretic Aspirin (ASA, Acetylsalicylic Acid) Analgesic, NSAID, antipyretic Non-Opioid Analgesics COMMON USES WHAT I NEED TO KNOW AS A

More information

General Patient Information Dr. David A. Branch, M.D.

General Patient Information Dr. David A. Branch, M.D. General Patient Information Dr. David A. Branch, M.D. **Please Print** Patient Name: Date of Birth: Social Security # Email Address: Patient Address: _ City: State: Zip Code: Phone : Marital Status: S

More information

MIGRAINE A MYSTERY HEADACHE

MIGRAINE A MYSTERY HEADACHE MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)

More information

Clinical Learning Days November 10, 2017

Clinical Learning Days November 10, 2017 Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion

More information

SIGN on the pharmacological management of migraine

SIGN on the pharmacological management of migraine GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR: M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated

More information

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL

More information

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL

More information

23, 2005 RESIDENT PHYSICIAN:

23, 2005 RESIDENT PHYSICIAN: TITLE: Migraine SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology DATE: March 23, 2005 RESIDENT PHYSICIAN: Jeffrey Buyten, MD FACULTY PHYSICIAN: David C. Teller, MD SERIES EDITORS: Francis

More information

Neurologic Disorders: Headache in Children

Neurologic Disorders: Headache in Children 1 of 12 17/06/2014 7:57 PM Print Close Neurologic Disorders: Headache in Children Sharon Whiting, MBBS, FRCPC Date of revision: February 2014 Headaches occur commonly in children and adolescents. They

More information

Clinical Policy: Sumatriptan Reference Number: CP.CPA.260 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Sumatriptan Reference Number: CP.CPA.260 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.260 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Farjam Farzam, M.D. Pediatric Neurology

Farjam Farzam, M.D. Pediatric Neurology Headaches in Children Farjam Farzam, M.D. Pediatric Neurology University of Kentucky Headaches in Children Common complaint in pediatric population. All age groups. 2-3 years old. Teenagers/Adolescents.

More information

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR: Core Safety Profile Active substance: Rizatriptan Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg P RMS: NL/H/PSUR/0002/001 Date of FAR: 23.05.2011 4.3 Contraindications

More information

Acute Migraine Treatment in Adults

Acute Migraine Treatment in Adults PL Detail-Document #301104 This PL Detail-Document gives subscribers additional insight related the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER November 2014 Acute Migraine Treatment

More information

Headache. Headache Case. Migraine Headache. Eric Kraus, MD. Types» Without aura (common)» With aura (classic)

Headache. Headache Case. Migraine Headache. Eric Kraus, MD. Types» Without aura (common)» With aura (classic) Headache Eric Kraus, MD Headache Case This 23 year-old female has headaches behind the right eye that cause her to lay down in a quiet room. They have a throbbing quality and she may vomit. Migraine Headache

More information

Page: 1 of 5. Sumatriptan Tablets and Nasal Spray (Imitrex) / sumatriptan and naproxen sodium (Treximet tablets)

Page: 1 of 5. Sumatriptan Tablets and Nasal Spray (Imitrex) / sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan (Imitrex / Treximet) Page: 1 of 5 Last Review Date: September 12, 2014 Sumatriptan

More information

Clinical Policy: Sumatriptan Reference Number: CP.HNMC.260 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Sumatriptan Reference Number: CP.HNMC.260 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: Reference Number: CP.HNMC.260 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen

More information

Come prepared: What you can expect:

Come prepared: What you can expect: Welcome! Thank you for choosing the Headache Clinic at University of Colorado Hospital for your health care needs. Targeting the best outcomes for patients, our providers bring together top expertise and

More information

100% Effective Natural Hormone Treatment Menopause, Andropause And Other Hormone Imbalances Impair Healthy Healing In People Over The Age Of 30!

100% Effective Natural Hormone Treatment Menopause, Andropause And Other Hormone Imbalances Impair Healthy Healing In People Over The Age Of 30! This Free E Book is brought to you by Natural Aging.com. 100% Effective Natural Hormone Treatment Menopause, Andropause And Other Hormone Imbalances Impair Healthy Healing In People Over The Age Of 30!

More information

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet

More information

Headache. Section 1. Migraine headache. Clinical presentation

Headache. Section 1. Migraine headache. Clinical presentation Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United

More information

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: March 16, 2018 Zomig Description Zomig / Zomig-ZMT

More information

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

The Pediatric Headache Handbook

The Pediatric Headache Handbook The Pediatric Headache Handbook For the Primary Care Physician Brought to you by the Division of Pediatric Neurology cardinalglennon.com Classification of headache patterns in children Acute onset of worst

More information

Headache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology

Headache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Headache and Facial Pain Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Introduction It is the most common neurologic complain The diagnosis usually

More information

Migraine in Children. Germano Falcao, MD Pediatric Neurology 03/07/2014

Migraine in Children. Germano Falcao, MD Pediatric Neurology 03/07/2014 Migraine in Children Germano Falcao, MD Pediatric Neurology 03/07/2014 Headaches in Children One of the most common concerns reported by children 3% for children age 3-7 years 4-11% for children age 7-11

More information

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67% PRIMARY CARE AND HEADACHE Sonja Potrebic MD PhD Regional Headache Specialist Kaiser LAMC 1 WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Column1 Primary Care 67% Primary Care Headache Specialty Other

More information

A PATIENT GUIDE FOR MANAGING PAIN

A PATIENT GUIDE FOR MANAGING PAIN A PATIENT GUIDE FOR MANAGING PAIN PAIN MANAGEMENT Knowing the Facts Pain can be controlled. Pain is common after surgery and with many types of illnesses. Most patients with acute and chronic pain can

More information

Package leaflet: Information for the user. Sumatriptan Amneal 100 mg tablets. sumatriptan

Package leaflet: Information for the user. Sumatriptan Amneal 100 mg tablets. sumatriptan Package leaflet: Information for the user Sumatriptan Amneal 50 mg tablets Sumatriptan Amneal 100 mg tablets sumatriptan Read all of this leaflet carefully before you start taking this medicine because

More information

Migraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options

Migraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options R. Michael Gallagher, DO; and F. Michael Cutrer, MD Abstract Objective: The safety and tolerability of medications used to treat

More information

Within 24 hours of treatment with another 5-HT 1 agonist, or an ergotaminecontaining

Within 24 hours of treatment with another 5-HT 1 agonist, or an ergotaminecontaining HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RELPAX safely and effectively. See full prescribing information for RELPAX. RELPAX (eletriptan hydrobromide)

More information

Department of Neurology Headache Questionnaire

Department of Neurology Headache Questionnaire Department of Neurology Headache Questionnaire first Name: last Name: Date of birth: primary care provider & clinic: previous neurologist: At what age did you have your first headache: What year did your

More information

ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM

ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM Conflict of Interest Declaration: Nothing to Disclose Presenter: John Robrock, MD Title of Presentation: Acute Migraine:

More information

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT

More information

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology

More information

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received

More information

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school

More information

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford Reflections on NICE Headache Guideline Dr Kay Kennis GPwSI in Headache, Bradford Overview The process of guideline development illustrated with the headache guideline Reflections on the process Key recommendations

More information

IMITREX (sumatriptan) nasal spray Initial U.S. Approval: 1992

IMITREX (sumatriptan) nasal spray Initial U.S. Approval: 1992 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX. IMITREX (sumatriptan)

More information

Neuroscience Institute Headache Center Intake Form. Please list ALL medications you are currently taking, including over-the-counter

Neuroscience Institute Headache Center Intake Form. Please list ALL medications you are currently taking, including over-the-counter Neuroscience Institute Headache Center Intake Form Please list ALL medications you are currently taking, including over-the-counter medications and supplements: Medication Allergies: Past Medical History:

More information

Understanding. Migraine. Amy, diagnosed in 1989, with her family.

Understanding. Migraine. Amy, diagnosed in 1989, with her family. Understanding Migraine Amy, diagnosed in 1989, with her family. What Is a Migraine? A migraine is a recurring moderate to severe headache. The pain usually occurs on one side of the head. It is typically

More information

Headache Board Review: Pharmacology of Drugs, Guidelines and Evidence-Based

Headache Board Review: Pharmacology of Drugs, Guidelines and Evidence-Based Headache Board Review: Pharmacology of Drugs, Guidelines and Evidence-Based Medicine Michael Marmura Thomas Jefferson University Department of Neurology, Jefferson Headache Center June 9, 2015 Michael.Marmura@Jefferson.edu

More information

ALSUMA (sumatriptan injection) 6 mg/0.5 ml for subcutaneous use Initial U.S. Approval: 1992

ALSUMA (sumatriptan injection) 6 mg/0.5 ml for subcutaneous use Initial U.S. Approval: 1992 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALSUMA safely and effectively. See full prescribing information for ALSUMA. ALSUMA (sumatriptan injection)

More information

Migraine Clinical Guideline

Migraine Clinical Guideline Migraine Clinical Guideline Definition: Migraine refers to a chronic neurological disorder characterized by episodic attacks often in association with enhanced sensitivity of the nervous system and activation

More information

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Injection

More information

*** Drug Safety Alert ***

*** Drug Safety Alert *** *** Drug Safety Alert *** May 6, 2013, the U.S. Food and Drug Administration (FDA) advised health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information